[{"address1": "4660 La Jolla Village Drive", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92122", "country": "United States", "phone": "650 800 3717", "website": "https://www.revbiosciences.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.", "fullTimeEmployees": 6, "companyOfficers": [{"maxAge": 1, "name": "Mr. James M. Rolke", "age": 54, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 400000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chester Stanley Zygmont III", "age": 43, "title": "CFO & Corporate Secretary", "yearBorn": 1980, "fiscalYear": 2022, "totalPay": 320000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sandra  Vedrick", "title": "Vice President of Human Resources & Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carol  Odle", "title": "Senior Director of Clinical Projects", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.4, "open": 3.48, "dayLow": 3.3001, "dayHigh": 3.6, "regularMarketPreviousClose": 3.4, "regularMarketOpen": 3.48, "regularMarketDayLow": 3.3001, "regularMarketDayHigh": 3.6, "beta": 0.15, "forwardPE": -0.16385543, "volume": 141754, "regularMarketVolume": 141754, "averageVolume": 374381, "averageVolume10days": 346530, "averageDailyVolume10Day": 346530, "bidSize": 800, "askSize": 800, "marketCap": 1347777, "fiftyTwoWeekLow": 2.4, "fiftyTwoWeekHigh": 63.9, "fiftyDayAverage": 7.85442, "twoHundredDayAverage": 19.037205, "currency": "USD", "enterpriseValue": -13280843, "floatShares": 205061, "sharesOutstanding": 396405, "sharesShort": 36087, "sharesShortPriorMonth": 19233, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.091000006, "heldPercentInsiders": 0.01334, "heldPercentInstitutions": 0.08085, "shortRatio": 0.05, "shortPercentOfFloat": 0.0917, "bookValue": 42.011, "priceToBook": 0.08093119, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": 875063, "trailingEps": -2.7, "forwardEps": -20.75, "enterpriseToEbitda": 1.765, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "REVB", "underlyingSymbol": "REVB", "shortName": "Revelation Biosciences, Inc.", "longName": "Revelation Biosciences, Inc.", "firstTradeDateEpochUtc": 1605623400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f994477e-3690-3dde-965e-6f9faa0f03d6", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.4, "targetHighPrice": 39.25, "targetLowPrice": 25.0, "targetMeanPrice": 32.13, "targetMedianPrice": 32.13, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 13994537, "totalCashPerShare": 66.669, "ebitda": -7524052, "quickRatio": 2.592, "currentRatio": 2.62, "returnOnAssets": -0.45324, "returnOnEquity": 0.15844, "freeCashflow": -3353955, "operatingCashflow": -6230917, "financialCurrency": "USD", "trailingPegRatio": null}]